Routine CFO onboarding filing. No immediate trading signal. Monitor for future equity grants or capital raises tied to the $5M cumulative capital vesting milestone.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $1.70entry
- T+1 · 4d ago −2.94%α −2.58% · $1.65
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Thomas John Freeburg filed a Form 3 initial statement of beneficial ownership after becoming CFO of Niki BioSolutions, Inc. The filing discloses stock options for 75,000 shares at $8.83, with vesting tied to milestones including an annual report, quarterly installments, capital raises, and change of control. This is a routine insider filing with no material financial impact.
Key Facts
- Thomas John Freeburg appointed CFO of Niki BioSolutions, Inc.
- Granted options to purchase 75,000 shares at $8.83 per share on September 1, 2026.
- Options vest in tranches: 15,000 upon first full Annual Report filing; 20,000 over eight quarters; 15,000 upon $5M cumulative capital; 25,000 upon change of control.
- All unvested options accelerate upon change of control.
- Form 3 filed on 2026-11-12, reporting period start 2026-10-09.
Financial Impact
Options for 75,000 shares at $8.83, representing approximately 0.75% of shares outstanding based on $5M market cap and $8.83 option price (implied ~566,000 shares outstanding). No immediate cash impact.
Risk Factors
- Options vesting milestones may create future dilution if capital raises occur.
- No financial data in filing to assess company performance.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001213900-26-118618 |
| Document: 0001213900-26-118618-index.html | 0001213900-26-118618 |
| Document: 0001213900-26-118618.txt | 0001213900-26-118618 |
Track record
8 reports on NIKI
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +62.57% at T+20 after the Oct 2, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 17, 2026today NT 10-Q Neutral 5/10 Entry $1.71 Now $1.50 −12.28% settles Dec 17
- Nov 12, 20265d ago 3 Neutral 2/10 Viewing Entry $1.70 Now $1.50 −11.76% settles Dec 11
- Oct 13, 20265w ago EFFECT Bearish 5/10 Entry $2.63 to $1.61 Now $1.50 +42.86% ▲ +38.67% +35.06% vs SPY
- Oct 2, 20266w ago S-3/A Bearish 6/10 Entry $4.73 to $1.77 Now $1.50 +68.28% ▲ +62.57% +60.10% vs SPY
- Sep 25, 20267w ago Press Release Neutral 2/10 Entry $4.76 to $1.83 Now $1.50 −68.49% ▼ −61.55% −60.08% vs SPY
- Sep 18, 20268w ago S-3/A Bearish 5/10 Entry $4.97 to $2.08 Now $1.50 +69.82% ▲ +58.15% +57.24% vs SPY
- Aug 27, 202611w ago S-3 Bearish 5/10 Entry $6.90 to $4.70 Now $1.50 +78.26% ▲ +31.88% +32.14% vs SPY
- Aug 7, 202614w ago 8-K Neutral 3/10 Entry $8.62 to $6.28 Now $1.50 −82.60% ▼ −27.15% −26.23% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers